



## Appendix A

### Claim Amendments

Claims 1-20 (Canceled)

21. (Currently Amended) An oral fixed combination administration form for an active compound, which is pyridine-2-ylmethylsulfinyl-1H-benzimidazole or a pharmaceutically acceptable salt thereof, which comprises the active compound in a capsule in two different administration forms, which release the active compound at two different points of time, wherein one administration form comprises the active compound together with a tablet disintegrant and bears a sustained-release coating film comprising a water-insoluble and physiologically tolerable plastic membrane having low swelling power in water and in which small soluble particles are embedded ~~which is customary per se for sustained-release compositions,~~ and wherein the other administration form comprises the active compound and bears ~~and~~ an enteric coating film.

22. (Previously Presented) An oral fixed combination administration form as claimed in claim 21, wherein the pyridine-2-ylmethylsulfinyl-1H-benzimidazole is pantoprazole.

23. (Previously Presented) An oral fixed combination administration form as claimed in claim 22, wherein each administration form is in pellet form.

24. (Previously Presented) An oral fixed combination

administration form as claimed in claim 22, wherein each administration form is in tablet form.

25. (Previously Presented) An oral fixed combination administration form as claimed in claim 22, wherein the tablet disintegrant is Crospovidone.

26. (Currently Amended) An oral fixed combination administration form as claimed in claim 22, wherein the sustained-release coating film ~~which is customary per se for sustained-release compositions~~ is a copolymer of acrylic and methacrylic acid esters having quaternary ammonium structures.

27. (Previously Presented) An oral fixed combination administration form as claimed in claim 22, which is suitable for once daily administration of pantoprazole or a pharmaceutically acceptable salt thereof instead of a twice daily administration.

28. (Previously Presented) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 21.

29. (Previously Presented) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 22.

30. (Previously Presented) A method of treating an amenable

disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 23.

31. (Previously Presented) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 24.

32. (Previously Presented) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 25.

33. (Previously Presented) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 26.

34. (Previously Presented) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 27.

35. (Previously Presented) An oral fixed combination administration form according to claim 21 wherein the administration form which comprises the active compound together with a tablet disintegrant releases said active compound only after gastric passage.

36. (Previously Presented) An oral fixed combination administration form according to claim 21 wherein the administration form which comprises the active compound together with a tablet disintegrant releases said active compound, once release thereof has commenced, within a short space of time, so that a rapidly rising and high active compound blood level is achieved.

37. (Previously Presented) An oral fixed combination administration form according to claim 21 wherein the administration form which comprises the active compound together with a tablet disintegrant releases said active compound after gastric passage spontaneously and completely.

38. (Previously Presented) An oral fixed combination administration form according to claim 21 wherein the administration form is that of a pharmaceutically acceptable salt selected from the group consisting of a calcium salt, a potassium salt and a sodium salt.

39. (Previously Presented) An oral fixed combination administration form according to claim 21 wherein the tablet disintegrant is a member select from the group consisting of a cellulose derivative, a starch, sodium carboxymethylstarch, bentonite, sodium alginate, pectin and crosslinked polyvinylpyrrolidone.

40. (Previously Presented) An oral fixed combination

administration form according to claim 21 wherein the tablet disintegrant is sodium carboxymethylcellulose or potato starch.

41. (Previously Presented) An oral fixed combination administration form according to claim 21 wherein each administration form has a core which contains a further auxiliary, filler, binder, stabilizer, or any combination thereof.

42. (Previously Presented) An oral fixed combination administration form according to claim 41 wherein the stabilizer is a pharmacologically tolerable alkali metal, alkaline earth metal or earth metal salt of a weak acid or a pharmacologically tolerable hydroxide or oxide of an alkaline earth metal or of an earth metal.

43. (Canceled)

44. (New) An oral fixed combination administration form according to claim 21, wherein the plastic membranes does not absorb more than 5% by weight of water in aqueous medium.

45. (New) An oral fixed combination administration form according to claim 21, wherein the small soluble particles are lactose crystals.

46. (New) An oral fixed combination administration form according to claim 21, wherein the small soluble particles are salts.

47. (New) An oral fixed combination administration form

according to claim 46, wherein the salts are ammonium salts.

48. (New) An oral fixed combination administration form according to claim 47, wherein the ammonium salts are ester groups of a copolymer of acrylic and methacrylic acid esters having quaternary ammonium structure.

49. (New) An oral fixed combination form according to claim 21, wherein the weight ratio of plastic to soluble particles is approximately 2:1 to 1:3.

50. (New) An oral fixed combination administration form according to claim 49, wherein the weight ratio of plastic to soluble particles is 4:3 to 4:5.

51. (New) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 44.

52. (New) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 45.

53. (New) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 46.

54. (New) A method of treating an amenable disorder of the

stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 47.

55. (New) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 48.

56. (New) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 49.

57. (New) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 50.